扩张型心肌病患者磁共振下心肌特征与室性心律失常的关系

孙一博, 王喆, 张悦坤, 等. 扩张型心肌病患者磁共振下心肌特征与室性心律失常的关系[J]. 临床心血管病杂志, 2022, 38(1): 48-53. doi: 10.13201/j.issn.1001-1439.2022.01.010
引用本文: 孙一博, 王喆, 张悦坤, 等. 扩张型心肌病患者磁共振下心肌特征与室性心律失常的关系[J]. 临床心血管病杂志, 2022, 38(1): 48-53. doi: 10.13201/j.issn.1001-1439.2022.01.010
SUN Yibo, WANG Zhe, ZHANG Yuekun, et al. The relationship between ventricular arrhythmia and myocardial characteristics in magnetic resonance imaging in patients with dilated cardiomyopathy[J]. J Clin Cardiol, 2022, 38(1): 48-53. doi: 10.13201/j.issn.1001-1439.2022.01.010
Citation: SUN Yibo, WANG Zhe, ZHANG Yuekun, et al. The relationship between ventricular arrhythmia and myocardial characteristics in magnetic resonance imaging in patients with dilated cardiomyopathy[J]. J Clin Cardiol, 2022, 38(1): 48-53. doi: 10.13201/j.issn.1001-1439.2022.01.010

扩张型心肌病患者磁共振下心肌特征与室性心律失常的关系

  • 基金项目:
    国家重点研发计划项目(No:2016YFC1301000)
详细信息

The relationship between ventricular arrhythmia and myocardial characteristics in magnetic resonance imaging in patients with dilated cardiomyopathy

More Information
  • 目的 探究非缺血性扩张型心肌病(NIDCM)患者磁共振下心肌强化特征与发生室性心律失常(VA)事件的关系,找出相关危险因素。方法 将2019年11月—2021年7月于郑州大学第一附属医院就诊的154例NIDCM患者纳入研究。根据发生VA事件的情况将其分为对照组及失常组,比较两组患者的一般资料及心脏磁共振延迟强化(LGE-CMR)下心肌特征。通过logistic回归分析相关危险因素,并应用受试者工作特征(ROC)曲线分析危险因素的诊断价值。结果 失常组的左室心肌质量(LVM)低于对照组,而年龄、左室舒张末期容积(EDV)、收缩末期容积(ESV)和胺碘酮的应用人数高于对照组(P< 0.05)。LGE-CMR下失常组心肌的灰色区占比高于对照组(P< 0.05),灰色区体积、强化区体积及占比无明显差异。logistic回归提示灰色区占比增加、年龄增大及ESV增大是发生VA的危险因素,而高LVM则为保护因素(P< 0.05)。其中灰色区占比、年龄及LVM诊断VA的曲线下面积(AUC)分别为0.662、0.646和0.607。结论 年龄和灰色区占比增大是NIDCM患者发生VA的独立危险因素,而较高的LVM起保护作用。
  • 加载中
  • 图 1  左心室心肌强化识别与划分

    Figure 1.  Recognition and division of left ventricular myocardial enhancement

    图 2  NIDCM患者VA风险因素的ROC曲线

    Figure 2.  The ROC curve of risk factors of ventricular arrhythmia in NIDCM patients

    表 1  两组患者一般资料比较

    Table 1.  Comparison of basic data between the two groups X±S, M(P25, P75)

    项目 对照组(66例) 失常组(88例) t/Z/χ2 P
    男/例(%) 53(80.30) 65(73.86) 0.873 0.350
    年龄/岁 47.56±13.98 54.16±11.19 -3.151 0.002
    身高/cm 171.92±9.35 170.53±7.68 0.809 0.421
    体重/kg 76.20±17.11 73.01±13.50 1.227 0.222
    糖尿病史/例(%) 8(12.12) 8(9.10) 0.372 0.542
    吸烟史/例(%) 25(37.88) 30(34.10) 0.236 0.627
    饮酒史/例(%) 20(30.30) 28(31.82) 0.040 0.841
    HbA1c/% 5.81(5.60,6.33) 6.0(5.64,6.50) -1.108 0.268
    TC/(mmol·L-1) 4.04±0.87 3.80±0.90 1.621 0.107
    TG/(mmol·L-1) 1.21(0.87,1.84) 1.17(0.89,1.55) -0.900 0.368
    HDL-C/(mmol·L-1) 0.99(0.83,1.17) 1.00(0.82,1.20) -0.210 0.834
    LDL-C/(mmol·L-1) 2.55±0.78 2.41±0.72 1.156 0.250
    Hb/(g·L-1) 148.00(133.50,163.50) 142.45(133.25,151.43) -1.864 0.062
    K/(mmol·L-1) 4.30±0.51 4.29±0.57 0.113 0.910
    Na/(mmol·L-1) 141.00(139.65,143.00) 141.00(139.00,142.80) -1.017 0.309
    Ca/(mmol·L-1) 2.31(2.23,2.38) 2.32(2.22,2.36) -0.897 0.369
    SCr/(μmol·L-1) 81.50(69.83,94.83) 79.00(67.70,90.00) -0.967 0.334
    UA/(μmol·L-1) 379.00(316.50,476.00) 370.00(315.25,464.75) -0.586 0.558
    TBil/(μmol·L-1) 12.73(9.53,18.46) 13.06(9.10,19.03) -0.343 0.732
    ALB/(g·L-1) 41.00(38.15,44.45) 40.60(38.40,43.60) -0.616 0.538
    NT-proBNP/(ng·L-1) 933.70(470.00,2273.75) 1147.00(398.58,3421.00) -1.102 0.270
    GFR/[mL·min-1·(1.73m2)-1] 92.80(76.79,104.18) 90.76(76.82,101.07) -1.080 0.280
    药物应用情况/例(%)
      β受体阻滞剂 59(89.40) 80(90.91) 0.098 0.754
      螺内酯 62(93.94) 81(92.05) 0.204 0.652
      呋塞米 54(81.82) 70(79.55) 0.124 0.725
      ACEI/ARB类 59(89.40) 84(95.45) 2.089 0.148
      他汀类 34(51.52) 38(43.18) 1.052 0.305
      地高辛 23(34.85) 28(31.82) 0.156 0.693
      胺碘酮 4(6.06) 20(22.73) 7.963 0.005
    ACEI/ARB:血管紧张素转化酶抑制剂/血管紧张素受体拮抗剂
    下载: 导出CSV

    表 2  比较两组间磁共振下心肌特征

    Table 2.  Evaluating the myocardial characteristics between two groups by using CMR X±S

    项目 对照组(66例) 失常组(88例) t/χ2 P
    EF/% 26.90±9.74 24.58±10.62 1.390 0.166
    EDV/mL 273.86±107.19 327.80±192.85 -2.200 0.029
    ESV/mL 204.99±95.63 255.86±168.16 -2.363 0.019
    SV/mL 71.29±23.41 72.04±35.89 -0.143 0.887
    CO/(L·min-1) 5.37±2.08 5.48±3.14 -0.232 0.817
    LVM/g 190.76±62.84 171.48±49.21 2.029 0.044
    无强化图像数/例(%) 9(13.64) 12(13.64) 0.000 1.000
    灰色区体积/cm3 8.37±6.76 9.76±5.79 -1.272 0.206
    灰色区占比/% 34.54±12.63 42.81±15.48 -3.292 0.001
    总强化区体积/cm3 24.62±16.49 24.62±15.59 -0.002 0.999
    总强化区占比/% 16.76±9.08 19.27±11.54 -1.360 0.176
    下载: 导出CSV

    表 3  NIDCM患者VA风险因素的多因素logistic回归分析

    Table 3.  Multivariate logistic regression results of VA risk factors for NIDCM patients

    变量 β SE OR 95%CI P
    年龄 0.036 0.017 1.036 1.003~1.070 0.031
    ESV 0.011 0.003 1.011 1.005~1.017 0.001
    LVM -0.018 0.006 0.982 0.971~0.993 0.002
    灰色区占比 0.039 0.017 1.039 1.006~1.073 0.019
    常量 -2.123 1.346 0.120
    下载: 导出CSV
  • [1]

    中华医学会心血管病学分会, 中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志, 2018, 34(5): 421-434.

    [2]

    Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy[J]. N Engl J Med, 2000, 342(15): 1077-1084. doi: 10.1056/NEJM200004133421502

    [3]

    Gulati A, Jabbour A, Ismail TF, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy[J]. JAMA, 2013, 309(9): 896-908. doi: 10.1001/jama.2013.1363

    [4]

    Nelson T, Garg P, Clayton RH, et al. The Role of cardiac MRI in the management of ventricular arrhythmias in ischaemic and non-ischaemic dilated cardiomyopathy[J]. Arrhythm Electrophysiol Rev, 2019, 8(3): 191-201. doi: 10.15420/aer.2019.5.1

    [5]

    Shenasa M. Fibrosis and ventricular arrhythmogenesis: role of cardiac MRI[J]. Card Electrophysiol Clin, 2019, 11(3): 551-562. doi: 10.1016/j.ccep.2019.06.002

    [6]

    Disertori M, Masè M, Ravelli F. Myocardial fibrosis predicts ventricular tachyarrhythmias[J]. Trends Cardiovasc Med, 2017, 27(5): 363-372. doi: 10.1016/j.tcm.2017.01.011

    [7]

    王璐静, 姜安谧, 金富伟, 等. CMR量化评价心肌梗死周围边缘带预测室性心律失常的研究进展[J]. 临床心血管病杂志, 2021, 37(6): 585-588. https://www.cnki.com.cn/Article/CJFDTOTAL-LCXB202106019.htm

    [8]

    中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会. 2020室性心律失常中国专家共识(2016共识升级版)[J]. 中华心律失常学杂志, 2020, 24(3): 111-115. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGXZ202003002.htm

    [9]

    Institute SCaI. "Seg3D" Volumetric Image Segmentation and Visualization. Scientific Computing and Imaging Institute(SCI). Available at: http://www.seg3d.org.

    [10]

    Schindelin J, Arganda-Carreras I, Frise E, et al. An open-source platform for biological-image analysis[J]. Nat Methods, 2012, 9(7): 676-682. doi: 10.1038/nmeth.2019

    [11]

    Gouda S, Abdelwahab A, Salem M, et al. Scar characteristics for prediction of ventricular arrhythmia in ischemic cardiomyopathy[J]. Pacing Clin Electrophysiol, 2015, 38(3): 311-318. doi: 10.1111/pace.12536

    [12]

    Schultheiss HP, Fairweather D, Caforio A, et al. Dilated cardiomyopathy[J]. Nat Rev Dis Primers, 2019, 5(1): 32. doi: 10.1038/s41572-019-0084-1

    [13]

    Becker M, Cornel JH, van de Ven PM, et al. The Prognostic value of late gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: a review and meta-analysis[J]. JACC Cardiovasc Imaging, 2018, 11(9): 1274-1284. doi: 10.1016/j.jcmg.2018.03.006

    [14]

    Willis MS, Yates CC, Schisler JC. Fibrosis in Disease: An Organ-Based Guide to Disease Pathophysiology and Therapeutic Considerations[J]. Springer, 2018: 111.

    [15]

    Berruezo A, Jáuregui B, Penela D. Towards an improved and personalized risk stratification of sudden cardiac death in dilated non-ischaemic cardiomyopathy: is the time for ejection fraction coming to an end?[J]. Eur Heart J Cardiovasc Imaging, 2021, 22(10): 1139-1141. doi: 10.1093/ehjci/jeab147

    [16]

    Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction[J]. JACC, 2006, 47(6): 1161-1166. doi: 10.1016/j.jacc.2005.11.045

    [17]

    Mandawat A, Chattranukulchai P, Mandawat A, et al. Progression of myocardial fibrosis in nonischemic DCM and association with mortality and heart failure outcomes[J]. JACC Cardiovasc Imaging, 2021, 14(7): 1338-1350. doi: 10.1016/j.jcmg.2020.11.006

    [18]

    Centurión OA, Alderete JF, Torales JM, et al. Myocardial fibrosis as a pathway of prediction of ventricular arrhythmias and sudden cardiac death in patients with nonischemic dilated cardiomyopathy[J]. Crit Pathw Cardiol, 2019, 18(2): 89-97. doi: 10.1097/HPC.0000000000000171

    [19]

    Barison A, Grigoratos C, Todiere G, et al. Myocardial interstitial remodelling in non-ischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance[J]. Heart Fail Rev, 2015, 20(6): 731-749. doi: 10.1007/s10741-015-9509-4

    [20]

    Balaban G, Halliday BP, Bai W, et al. Scar shape analysis and simulated electrical instabilities in a non-ischemic dilated cardiomyopathy patient cohort[J]. PLoS Comput Biol, 2019, 15(10): e1007421. doi: 10.1371/journal.pcbi.1007421

    [21]

    Chen Z, Sohal M, Voigt T, et al. Myocardial tissue characterization by cardiac magnetic resonance imaging using T1 mapping predicts ventricular arrhythmia in ischemic and non-ischemic cardiomyopathy patients with implantable cardioverter-defibrillators[J]. Heart Rhythm, 2015, 12(4): 792-801. doi: 10.1016/j.hrthm.2014.12.020

    [22]

    Pham VT, Lin C, Tran TT, et al. Predicting ventricular tachyarrhythmia in patients with systolic heart failure based on texture features of the gray zone from contrast-enhanced magnetic resonance imaging[J]. J Cardiol, 2020, 76(6): 601-609. doi: 10.1016/j.jjcc.2020.06.020

    [23]

    Estner HL, Zviman MM, Herzka D, et al. The critical isthmus sites of ischemic ventricular tachycardia are in zones of tissue heterogeneity, visualized by magnetic resonance imaging[J]. Heart Rhythm, 2011, 8(12): 1942-1949. doi: 10.1016/j.hrthm.2011.07.027

    [24]

    Oduneye SO, Pop M, Shurrab M, et al. Distribution of abnormal potentials in chronic myocardial infarction using a real time magnetic resonance guided electrophysiology system[J]. Journal of cardiovascular magnetic resonance, 2015, 17(1): 27. doi: 10.1186/s12968-015-0133-1

  • 加载中

(2)

(3)

计量
  • 文章访问数:  1243
  • PDF下载数:  314
  • 施引文献:  0
出版历程
收稿日期:  2021-08-18
刊出日期:  2022-01-13

目录